Abstract: A method of producing induced exosomes, the method comprising: contacting an isolated population of stem cells with an amount of a prostaglandin E receptor 4 (EP4) antagonist effective for inducing release of exosomes, whereby induced exosomes are released from the stem cells, and isolating the induced exosomes.

Abstract: The present disclosure relates to the technical field of polymer material, and discloses a device and method for online preparation of a modified polylactic acid material with a polylactic acid melt. The device comprises a twin-screw extruder, a first solid modifier hopper, a polylactic acid melt pipeline and a polylactic acid melt feedstock metering pump, wherein the first solid modifier hopper is connected with Zone I of the twin-screw extruder, the polylactic acid melt pipeline is connected with Zone IV of the twin-screw extruder. The method for online preparation of modified polylactic acid material with the device can avoid degradation of the polylactic acid caused by the secondary processing, improve mechanical property of the prepared polylactic acid and reduce production cost.

Abstract: The present disclosure relates to the technical fields of genetic engineering and microbial fermentation, and discloses a recombinant strain for producing L-lactic acid, wherein the recombinant strain is obtained by genetically modifying a starting strain, the activity of D-lactate dehydrogenase of the recombinant strain is weakened or inactivated, and the activity of L-lactate dehydrogenase is enhanced, as compared with the starting strain. The present invention can significantly improve the fermentation effect, the yield of the L-lactic acid and the optical purity of the product L-lactic acid.

Abstract: The present disclosure relates to the technical field of biotechnology and polymer synthesis, and discloses a method for producing polylactic acid, the method comprises the following steps: (i) inoculating a lactic acid fermentation strain into a lactic acid fermentation culture medium to perform a fermentation, so as to obtain a fermentation broth containing lactate; (ii) separating the fermentation broth to obtain a lactic acid; (iii) synthesizing a polymer-grade lactide by using the lactic acid as a raw material; (iv) subjecting the polymer-grade lactide to a polymerization reaction in a polymerization reaction device to obtain a polylactic acid. Through the above technical solution, the polylactic acid can be efficiently produced in the present disclosure.

Abstract: The present invention relates to the field of devolatilization, and discloses a polylactic acid devolatilization evaporator, which comprises: a container comprising a cylinder; an agitating shaft coaxial with the cylinder; an agitating belt connected to the agitating shaft and arranged in a spiral shape around the central axis of the cylinder, comprising an outer belt surface facing the inner circumferential surface of the cylinder and spaced apart from the inner circumferential surface of the cylinder. With the above technical scheme, the agitating belt makes the materials distributed more uniformly on the inner circumferential surface of the cylinder and form a thin layer in uniform thickness, thereby avoids agglomeration of the materials, facilitates uniform heating of the materials, avoids deterioration (e.g., darkened color) of the materials owing to non-uniform heating of the materials and excessive retention time in a high-temperature environment, and improves product quality.

Abstract: An isolated antibody, comprising a light-chain CDR1 (L-CDR1) having the sequence of SEQ ID NO: 1, SEQ ID NO: 7, or SEQ ID NO: 14; a light-chain CDR2 (L-CDR2) having the sequence of SEQ ID NO: 2 or SEQ ID NO: 15; a light-chain CDR3 (L-CDR3) having the sequence of SEQ ID NO: 3, SEQ ID NO: 8, SEQ ID NO: 21, or SEQ ID NO: 24; a heavy-chain CDR1 (H-CDR1) having the sequence of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 16, or SEQ ID NO: 25; a heavy-chain CDR2 (H-CDR2) having the sequence of SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 22, or SEQ ID NO: 26; and a heavy-chain CDR3 (H-CDR3) having the sequence of SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 23, or SEQ ID NO: 27, wherein the antibody specifically binds to A?1-42 or an N-terminal modified form thereof.

Abstract: An isolated antibody, comprising: heavy chain complementary determining regions CDR1, CDR2, and CDR3 of a heavy chain variable region sequence selected from SEQ ID NOs: 2, 6, 10, and 14; and light chain complementary determining regions CDR1, CDR2, and CDR3 of a light chain variable region sequence selected from SEQ ID NOs: 4, 8, 12, and 16; wherein the antibody binds specifically to a RSPO3 protein.

Abstract: Described herein are an immunogenic peptide containing the sequence of CLDSLGQWN (SEQ ID NO:2) and a method of using the peptide for treating cancer.

Abstract: The present invention relates to microbiota compositions and their preparation methods and uses. Particularly, the present invention provides microbiota compositions collected from a dual-specificity phosphatase 6 (dusp6) deficient mammal, which is effective in altering a relative abundance of gut microbiota and also useful in reducing body weight, fat mass, and/or size of adipocytes and increasing oxygen consumption and/or energy expenditure and thus can be used to treat or prevent obesity or its associated disorders or conditions in a subject in need.

Abstract: A hydrodynamic shuttling chip device comprising an array of single-cell trapping units is disclosed. Each unit comprises: (a) an incoming channel with a cell capture site; (b) a cell culture chamber located posterior to the cell capture site, having a receiving site spaced apart from the cell capture site at a distance of g; (c) a trapping channel located between the cell capture site and the receiving site; (d) a chamber channel located posterior to and in fluidic connection with the cell culture chamber; and (e) a by-pass channel, located lateral to the incoming channel, chamber and chamber channel and having a first end and a second end opposite to the first end, the first end branching out from the incoming channel immediately prior to the cell capture site and the second end joining the chamber channel. A method of capturing single cells of more than one type is also disclosed.

Abstract: Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.

Abstract: Heterocyclic compounds of Formula (I) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds. Further disclosed are methods of using one of the heterocyclic compounds for mobilizing hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation, and for treating tissue injury, cancer, inflammatory disease, and autoimmune disease.

Abstract: A fusion protein, comprising: (i) a first vascular endothelial growth factor (VEGF) isoform, and (ii) a second VEGF isoform, and (iii) a dimerization domain between the first isoform and the second isoform, wherein the first isoform and the second isoform are selected from VEGF121 and VEGF165.

Abstract: The present disclosure provides a method for domesticating Saccharomyces cerevisiae which is resistant to fermentation inhibitors, high temperature and high concentration of ethanol. The method comprises a primary domestication and a secondary domestication of the S. cerevisiae, wherein the primary domestication comprises the steps of replacing the fermented mash with fresh liquefied mash and continuing fermentation when the ethanol content in the fermented mash reaches a higher concentration (>12% (v/v)), the replacement is performed for at least 20 times, and the time interval of replacements is 20-30 hours; the secondary domestication comprises the steps of performing high-temperature domestication on the primary domesticated strain by a temperature gradient and replacing the fermented mash for multiple times, wherein the temperature is raised by 0.5° C.-2° C. every 18-24 times of replacement. The domesticated S.

Abstract: Disclosed is an adapted Madin-Darby canine kidney cell line capable of suspension culture in the absence of serum, and a chemically-defined medium for culture of the adapted MDCK cell line. Further disclosed are culture methods for growing the adapted MDCK cell line and methods for producing a vaccine from the adapted MDCK cell line grown in the chemically-defined medium.

Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.

Abstract: A method of treating a hair loss condition, comprising administering a Notch signaling pathway activator to a subject in need thereof.

Abstract: The present invention relates to a three-dimensional (3D) tissue-like implant for transplanting to a subject in need comprising a cell cluster comprising mesenchymal stem cells (MSCs) and specific cells differentiated therefrom. The present invention also relate to a method of preparing a 3D-tissue-like implant from MSCs, particularly by seeding MSCs in alginate scaffolds and culturing the alginate scaffolds with MSCs in a 3-D perfusion condition. Further, the present invention provides a method for treating a defect in a recipient patient in need by administering a 3D tissue-like implant as described herein to the patient at a defective site e.g. a bone defective site.

Abstract: A non-invasive system, and method for simple, quantitative screening for mTBI and other forms of mid cognitive impairment using a visuo-motor performance test (for example, a submaximal grip test) in response to visual feedback to quantitatively measure the intra-individual variability of performance metric for initial screening of patients with mild traumatic brain injury (mTBI), and other neurological disorders. The system and method can be administered in minutes, by any level of caregiver, in any environment including military in-the-field or sports on-field deployments, and is useful in screening those truly injured from those disguising or mimicking injury. In addition to screening, the system and method can be used to monitor and/or detect changes to intra-individual variability over time by comparison to a baseline, which in turn is helpful in determining estimated recovery trajectory or other related information.

Abstract: The present disclosure provides a method for domesticating Saccharomyces cerevisiae which is resistant to fermentation inhibitors, high temperature and high concentration of ethanol. The method comprises a primary domestication and a secondary domestication of the S. cerevisiae, wherein the primary domestication comprises the steps of replacing the fermented mash with fresh liquefied mash and continuing fermentation when the ethanol content in the fermented mash reaches a higher concentration (>12% (v/v)), the replacement is performed for at least 20 times, and the time interval of replacements is 20-30 hours; the secondary domestication comprises the steps of performing high-temperature domestication on the primary domesticated strain by a temperature gradient and replacing the fermented mash for multiple times, wherein the temperature is raised by 0.5° C.-2° C. every 18-24 times of replacement. The domesticated S.